

---

**SUBSTITUTE SENATE BILL 6416**

---

**State of Washington**

**56th Legislature**

**2000 Regular Session**

**By** Senate Committee on Health & Long-Term Care (originally sponsored by Senators Thibaudeau, Deccio, Wojahn, Rasmussen, Johnson, Franklin, B. Sheldon, Costa, Prentice, Sheahan, Fraser, Swecker, McAuliffe, Winsley, Kohl-Welles, Haugen, Benton, Spanel, McDonald and Oke)

Read first time 02/01/2000.

1 AN ACT Relating to needlesticks and sharps protections; adding a  
2 new section to chapter 49.17 RCW; and creating a new section.

3 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

4 NEW SECTION. **Sec. 1.** The legislature finds that opportunities to  
5 improve bloodborne pathogens standards arise when product engineering  
6 improvements result in safer medical devices.

7 NEW SECTION. **Sec. 2.** A new section is added to chapter 49.17 RCW  
8 to read as follows:

9 (1) The department shall, by March 1, 2001, adopt rules revising  
10 the bloodborne pathogens standard governing occupational exposure to  
11 blood and other potentially infectious materials. The rules must  
12 require product evaluation in accordance with subsection (3) of this  
13 section, beginning no later than April 1, 2001. The rules must also  
14 embody a bloodborne pathogens standard meeting the requirements of  
15 subsection (4) of this section.

16 (2) The definitions in this subsection apply to all rules regarding  
17 occupational exposure to bloodborne pathogens and other potentially  
18 infectious materials.

1 (a) "Bloodborne pathogens" means pathogenic microorganisms that are  
2 present in human blood and can cause disease in humans. These  
3 pathogens include, but are not limited to, hepatitis B virus, hepatitis  
4 C virus, and human immunodeficiency virus.

5 (b) "Engineering controls" means controls including, but not  
6 limited to, sharps disposal containers, needleless systems, and sharps  
7 with engineered sharps injury protection that isolate or remove the  
8 bloodborne pathogens hazard from the workplace.

9 (c) "Engineered sharps injury protection" means either:

10 (i) A physical attribute built into a needle device used for  
11 withdrawing body fluids, accessing a vein or artery, or administering  
12 medications or other fluids, that effectively reduces the risk of an  
13 exposure incident by a mechanism such as barrier creation, blunting,  
14 encapsulation, withdrawal, retraction, destruction, or other effective  
15 mechanisms; or

16 (ii) A physical attribute built into any other type of needle  
17 device, or into a nonneedle sharp, that effectively reduces the risk of  
18 an exposure incident.

19 (d) "Front-line health care worker" means a nonmanagerial employee  
20 responsible for direct patient care with potential occupational  
21 exposure to sharps-related injuries.

22 (e) "Needleless system" means a device that does not use needles  
23 for:

24 (i) The withdrawal of body fluids after initial venous or arterial  
25 access is established;

26 (ii) The administration of medication or fluids; and

27 (iii) Any other procedure involving the potential for an exposure  
28 incident.

29 (f) "Sharp" means any object used or encountered in a health care  
30 setting that can be reasonably anticipated to penetrate the skin or any  
31 other part of the body, and to result in an exposure incident,  
32 including, but not limited to, needle devices, scalpels, lancets, and  
33 broken capillary tubes.

34 (g) "Sharps injury" means any injury caused by a sharp, including,  
35 but not limited to, cuts, abrasions, or needlesticks.

36 (h) "Sharps injury log" means a written or electronic record  
37 satisfying the requirements of subsection (4)(b)(iii) of this section.

38 (3)(a) The rules adopted under subsection (1) of this section must  
39 require each employer to adopt a methodology for product review and

1 evaluation of available needleless systems and sharps with engineered  
2 sharps injury protections, including an evaluation of reliable sources  
3 of information from such sources as government agencies, employer  
4 organizations, labor organizations, and other sources deemed  
5 appropriate, to enable the employer to select the appropriate  
6 engineering controls in the categories listed below for implementation  
7 no later than the effective date of the rules adopted under subsection  
8 (1) of this section. The employer's methodology for review and  
9 evaluation must include input from front-line health care workers who  
10 will be engaged in the use of the devices in accordance with the  
11 provisions of subsection (4)(b) of this section, as well as other  
12 appropriate sources in the employer's organization. Product review and  
13 evaluation should include, but not be limited to, the following  
14 categories of devices as used in the employer's facilities:

- 15 (i) Intravenous catheters;
- 16 (ii) Intravenous access devices and intravenous connectors;
- 17 (iii) Vacuum tube blood collection devices;
- 18 (iv) Blood-drawing devices such as phlebotomy needle/tube holders,  
19 butterfly-type devices, and syringes;
- 20 (v) Syringes used for purposes other than blood drawing;
- 21 (vi) Suture needles;
- 22 (vii) Scalpel devices; and
- 23 (viii) Any other category of medical device used at the employer's  
24 facility where there is a sharps injury risk.

25 (b) For each category of device, product review and evaluation must  
26 be conducted with meaningful input from front-line health care workers  
27 representing areas in which they will be used, as well as infection  
28 control professionals and representatives of other disciplines as  
29 appropriate. In addition, the department, in consultation with the  
30 Washington state hospital association and other provider associations,  
31 shall determine means by which these associations can help employers  
32 meet the requirements of this subsection. The product evaluation  
33 period should continue for not less than six months from the date of  
34 commencement.

35 (4) The rules adopted under subsection (1) of this section must  
36 require each employer to develop a written exposure control plan to be  
37 completed no later than three months following the effective date of  
38 the rules, establish sharps injury logs no later than three months  
39 following the effective date of the rules, and implement engineering

1 controls as soon as possible but no later than nine months after the  
2 effective date of the rules. The rules must include, but are not  
3 limited to, the following:

4 (a) A requirement that the most effective available needleless  
5 systems and sharps with engineered sharps injury protection be included  
6 as engineering and work practice controls. However, needleless systems  
7 and sharps with engineered sharps injury protection are not required  
8 if:

9 (i) Such devices are not available in the marketplace;

10 (ii) The employer, with input from the evaluation committee,  
11 described in (b)(v) of this subsection, determines by means of  
12 objective product evaluation criteria that use of such devices may  
13 jeopardize patient safety if utilized for a class or type of procedure,  
14 or for a class or type of procedure when performed on a certain type of  
15 patient;

16 (iii) A certified or licensed health care worker directly involved  
17 in the patient's care determines, in the reasonable exercise of  
18 clinical judgment, that use of such devices will jeopardize the  
19 patient's safety or the success of the particular medical procedure  
20 involving the patient. A health care worker who makes such a  
21 determination must report, in accordance with the requirements of  
22 (b)(vi) of this subsection, the reasons for failing to use an approved  
23 needleless system or sharp with engineered sharps injury protection;

24 (iv) The employer can demonstrate by means of objective product  
25 evaluation criteria that use of such devices are not more effective in  
26 preventing exposure incidents than the alternative used by the  
27 employer; or

28 (v) The employer can demonstrate, with respect to an engineering  
29 control which has not been available in the marketplace for twelve  
30 months, that reasonably specific and reliable information is not  
31 available regarding the safety performance of the engineering control  
32 for the employer's procedures, and that the employer is actively  
33 determining by means of objective product evaluation criteria whether  
34 the use of the engineering control will reduce the risk of exposure  
35 incidents occurring in the employer's workplace;

36 (b) A requirement that each employer develop and implement an  
37 effective written exposure control plan that includes, but is not  
38 limited to, procedures for:

1 (i) Identifying and selecting needleless systems and sharps with  
2 engineered sharps injury protection. Any procedure adopted should  
3 provide that the evaluation committee described in (b)(v) of this  
4 subsection will have meaningful input into the identification and  
5 evaluation of such devices;

6 (ii) Updating the written exposure control plan when necessary to  
7 reflect progress in implementing needleless systems and sharps with  
8 engineered sharps injury protection as determined by the evaluation  
9 committee described in (b)(v) of this subsection, but in no event less  
10 than once every year;

11 (iii) Recording information concerning exposure incidents in a  
12 sharps injury log, including, but not limited to, the following  
13 information, if known:

14 (A) The date and time of the exposure incident;

15 (B) The type and brand of sharp involved in the exposure incident;

16 and

17 (C) The description of the exposure incident that includes:

18 (I) The job classification of the exposed employee;

19 (II) The department or work area where the exposure incident  
20 occurred;

21 (III) The procedure that the exposed employee was performing at the  
22 time of the incident;

23 (IV) How the incident occurred;

24 (V) The body part involved in the exposure incident;

25 (VI) If the sharp had engineered sharps injury protection, whether  
26 the protective mechanism was activated, and whether the injury occurred  
27 before the protective mechanism was activated, during activation of the  
28 mechanism, or after activation of the mechanism;

29 (VII) If the sharp had no engineered sharps injury protection,  
30 whether and how such a mechanism could have prevented the injury, as  
31 well as the basis for the assessment; and

32 (VIII) An assessment of whether any other engineering,  
33 administrative, or work practice control could have prevented the  
34 injury, as well as the basis for the assessment;

35 (iv) Ensuring that all front-line health care workers are trained  
36 in, and demonstrate their ability to use, engineering controls before  
37 they are introduced into the clinical setting;

38 (v) Establishment by the employer of an evaluation committee to  
39 advise the employer on the implementation of the requirements of this

1 section. At least half the members of the committee must be either  
2 front-line health care workers or representatives of employee  
3 organizations which represent front-line health care workers in job  
4 classifications impacted by the requirements of this section, including  
5 but not limited to nurses, medical assistants or nurses aides,  
6 technicians who handle or process sharps, phlebotomists, and  
7 physicians. An employer that is affiliated with, or affiliated for  
8 certain purposes with, a multistate or multilocation health care  
9 organization is in compliance with this section if it relies on an  
10 evaluation committee established by the organization centrally, so long  
11 as implementation of the advice of the centralized evaluation committee  
12 is accomplished in a manner that ensures communication with, training  
13 of, and feedback from affected staff of the local employer. Members of  
14 the evaluation committee must be provided demonstrations of the use of  
15 engineering controls and must be trained in product evaluation criteria  
16 prior to the commencement of any product evaluation; and

17 (vi) Ensuring all determinations pursuant to (a)(iii) of this  
18 subsection are reported in writing, including the date, time, patient,  
19 and procedure involved, and a statement of why the employee failed to  
20 use an approved needleless system or sharp with engineered sharps  
21 injury protections.

22 (5) In complying with this section, an employer with no more than  
23 ten full-time equivalent employees, responsible for direct patient care  
24 with potential occupational exposure to sharps related injuries, at any  
25 time during the calendar year immediately preceding the current  
26 calendar year may:

27 (a) Evaluate new technology through its own evaluation committee,  
28 as defined in subsection (4)(b)(v) of this section, a joint evaluation  
29 committee, established by multiple small business employers, that meets  
30 the requirements of subsection (4)(b)(v) of this section;

31 (b) Use a joint evaluation committee to develop and update the  
32 written procedure for identifying and selecting devices as required by  
33 subsection (4)(b)(i) and (ii) of this section; and

34 (c) Comply with the provisions of subsection (4)(b)(iii) of this  
35 section by recording the required sharps injury data in its OSHA 200  
36 log.

37 (6) The department shall promulgate additional amendments to the  
38 bloodborne pathogens standard necessary to implement this section; and,  
39 to the extent that funds are available, evaluate the impact of this

1 section on the reduction of needlestick and sharps injuries and costs  
2 of employer operations.

3 (7) To assist employers in complying with the requirements of the  
4 bloodborne pathogens standard adopted under this section, the  
5 department shall compile and maintain a list of needleless systems and  
6 sharps with engineered sharps injury protection. The list may be  
7 developed from existing sources of information including, but not  
8 limited to, the federal food and drug administration, the federal  
9 centers for disease control, the national institute of occupational  
10 safety and health, and the United States department of veterans  
11 affairs.

12 (8) Nothing in this section provides an exemption or other basis of  
13 appeal in relation to the existing requirements of the bloodborne  
14 pathogens standard and any other requirements adopted under the  
15 authority of RCW 49.17.040 and 49.17.050.

16 (9) To the extent they exceed the existing bloodborne pathogens  
17 standard and any other requirements adopted under the authority of RCW  
18 49.17.040 and 49.17.050, the requirements of this section do not apply  
19 to the practice of dentistry.

20 (10) The department shall consult with the Washington state  
21 hospital association and other provider associations to develop policy  
22 guidance, as effective as federal enforcement and consistent with  
23 existing bloodborne pathogens standards and any other requirements  
24 adopted under the authority of this chapter, which addresses compliance  
25 requirements prior to the implementation of regulations under this  
26 section.

--- END ---